4.7 Review

Vaccination of immunocompromised patients

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 18, Issue -, Pages 93-99

Publisher

ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2012.03971.x

Keywords

Cancer; influenza; pneumococci; solid organ transplantation; stem cell transplantation; vaccination

Funding

  1. VICAL Inc
  2. Astellas Pharma
  3. GSK
  4. Merck

Ask authors/readers for more resources

Clin Microbiol Infect 2012; 18 (Suppl. 5): 9399 Abstract Vaccination of immunocompromised patients is challenging both regarding efficacy and safety. True efficacy data are lacking so existing recommendations are based on immune responses and safety data. Inactivated vaccines can generally be used without risk but the patients who are most at risk for infectious morbidity and mortality as a result of their severely immunosuppressed state are also those least likely to respond to vaccination. However, vaccination against pneumococci, Haemophilus influenzae and influenza are generally recommended. Live vaccines must be used with care because the risk for vaccine-associated disease exists.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available